206 related articles for article (PubMed ID: 23983160)
21. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
22. The Performance of Fixed-Horizon, Look-Ahead Procedures Compared to Backward Induction in Bayesian Adaptive-Randomization Decision-Theoretic Clinical Trial Design.
Lipsky AM; Lewis RJ
Int J Biostat; 2019 Feb; 15(1):. PubMed ID: 30726189
[TBL] [Abstract][Full Text] [Related]
23. A systematic review of randomised controlled trials with adaptive and traditional group sequential designs - applications in cardiovascular clinical trials.
Zhang J; Saju C
BMC Med Res Methodol; 2023 Sep; 23(1):200. PubMed ID: 37679710
[TBL] [Abstract][Full Text] [Related]
24. Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research?
Li G; Sajobi TT; Menon BK; Korngut L; Lowerison M; James M; Wilton SB; Williamson T; Gill S; Drogos LL; Smith EE; Vohra S; Hill MD; Thabane L;
J Clin Epidemiol; 2016 Dec; 80():16-24. PubMed ID: 27555082
[TBL] [Abstract][Full Text] [Related]
25. An overview of methodological considerations regarding adaptive stopping, arm dropping, and randomization in clinical trials.
Granholm A; Kaas-Hansen BS; Lange T; Schjørring OL; Andersen LW; Perner A; Jensen AKG; Møller MH
J Clin Epidemiol; 2023 Jan; 153():45-54. PubMed ID: 36400262
[TBL] [Abstract][Full Text] [Related]
26. A Bayesian response-adaptive trial in tuberculosis: The endTB trial.
Cellamare M; Ventz S; Baudin E; Mitnick CD; Trippa L
Clin Trials; 2017 Feb; 14(1):17-28. PubMed ID: 27559021
[TBL] [Abstract][Full Text] [Related]
27. Covariate adjustment in Bayesian adaptive randomized controlled trials.
Willard J; Golchi S; Moodie EE
Stat Methods Med Res; 2024 Mar; 33(3):480-497. PubMed ID: 38327082
[TBL] [Abstract][Full Text] [Related]
28. Simulation study for evaluating the performance of response-adaptive randomization.
Du Y; Wang X; Jack Lee J
Contemp Clin Trials; 2015 Jan; 40():15-25. PubMed ID: 25460340
[TBL] [Abstract][Full Text] [Related]
29. TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis.
Cole M; Yap C; Buckley C; Ng WF; McInnes I; Filer A; Siebert S; Pratt A; Isaacs JD; Stocken DD
Trials; 2021 Jul; 22(1):433. PubMed ID: 34229728
[TBL] [Abstract][Full Text] [Related]
30. Group sequential designs for developing and testing biomarker-guided personalized therapies in comparative effectiveness research.
Lai TL; Liao OY; Kim DW
Contemp Clin Trials; 2013 Nov; 36(2):651-63. PubMed ID: 23994669
[TBL] [Abstract][Full Text] [Related]
31. Adaptive designs in public health: Vaccine and cluster randomized trials go Bayesian.
Harari O; Park JJH; Lat PK; Mills EJ
Stat Med; 2024 Jun; 43(14):2811-2829. PubMed ID: 38716764
[TBL] [Abstract][Full Text] [Related]
32. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
33. Adaptive design of confirmatory trials: Advances and challenges.
Lai TL; Lavori PW; Tsang KW
Contemp Clin Trials; 2015 Nov; 45(Pt A):93-102. PubMed ID: 26079372
[TBL] [Abstract][Full Text] [Related]
34. Response-adaptive decision-theoretic trial design: operating characteristics and ethics.
Lipsky AM; Lewis RJ
Stat Med; 2013 Sep; 32(21):3752-65. PubMed ID: 23558674
[TBL] [Abstract][Full Text] [Related]
35. Frequentist operating characteristics of Bayesian optimal designs via simulation.
Zhang Y; Trippa L; Parmigiani G
Stat Med; 2019 Sep; 38(21):4026-4039. PubMed ID: 31215685
[TBL] [Abstract][Full Text] [Related]
36. A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen.
Fiore LD; Brophy M; Ferguson RE; D'Avolio L; Hermos JA; Lew RA; Doros G; Conrad CH; O'Neil JA; Sabin TP; Kaufman J; Swartz SL; Lawler E; Liang MH; Gaziano JM; Lavori PW
Clin Trials; 2011 Apr; 8(2):183-95. PubMed ID: 21478329
[TBL] [Abstract][Full Text] [Related]
37. Bayesian enrichment strategies for randomized discontinuation trials.
Trippa L; Rosner GL; Müller P
Biometrics; 2012 Mar; 68(1):203-11. PubMed ID: 21714780
[TBL] [Abstract][Full Text] [Related]
38. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.
Coffey CS; Levin B; Clark C; Timmerman C; Wittes J; Gilbert P; Harris S
Clin Trials; 2012 Dec; 9(6):671-80. PubMed ID: 23250942
[TBL] [Abstract][Full Text] [Related]
39. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial.
Yuan Y; Huang X; Liu S
Stat Med; 2011 May; 30(11):1218-29. PubMed ID: 21432894
[TBL] [Abstract][Full Text] [Related]
40. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.
Berger ML; Dreyer N; Anderson F; Towse A; Sedrakyan A; Normand SL
Value Health; 2012; 15(2):217-30. PubMed ID: 22433752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
